293 related articles for article (PubMed ID: 25803811)
1. Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1.
Yamamoto S; Otsu M; Matsuzaka E; Konishi C; Takagi H; Hanada S; Mochizuki S; Nakauchi H; Imai K; Tsuji K; Ebihara Y
PLoS One; 2015; 10(3):e0120841. PubMed ID: 25803811
[TBL] [Abstract][Full Text] [Related]
2. Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib.
Landberg N; Dreimane A; Rissler M; Billström R; Ågerstam H
Eur J Haematol; 2017 Nov; 99(5):442-448. PubMed ID: 28881484
[TBL] [Abstract][Full Text] [Related]
3. Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR‑FGFR1 fusion.
Qiu XH; Li F; Cao HQ; Shao JJ; Mei JG; Li HQ; Zhai YP
Mol Med Rep; 2017 Mar; 15(3):1024-1030. PubMed ID: 28138694
[TBL] [Abstract][Full Text] [Related]
4. Functional characterization, localization, and inhibitor sensitivity of the TPR-FGFR1 fusion in 8p11 myeloproliferative syndrome.
Malli T; Buxhofer-Ausch V; Rammer M; Erdel M; Kranewitter W; Rumpold H; Marschon R; Deutschbauer S; Simonitsch-Klupp I; Valent P; Muellner-Ammer K; Sebesta C; Birkner T; Webersinke G
Genes Chromosomes Cancer; 2016 Jan; 55(1):60-8. PubMed ID: 26391436
[TBL] [Abstract][Full Text] [Related]
5. [8p11 myeloproliferative syndrome with CEP110-FGFR1 fusion in a patient].
Chao H; Chen S; Zhou M; Lu X; Zhang X; Pan J; Wu C; Zhang R
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Oct; 32(5):679-82. PubMed ID: 26418991
[TBL] [Abstract][Full Text] [Related]
6. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome.
Chase A; Grand FH; Cross NC
Blood; 2007 Nov; 110(10):3729-34. PubMed ID: 17698633
[TBL] [Abstract][Full Text] [Related]
7. Molecular monitoring of 8p11 myeloproliferative syndrome in an infant.
Zhang WW; Habeebu S; Sheehan AM; Naeem R; Hernandez VS; Dreyer ZE; López-Terrada D
J Pediatr Hematol Oncol; 2009 Nov; 31(11):879-83. PubMed ID: 19829149
[TBL] [Abstract][Full Text] [Related]
8. Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and
Wehrli M; Oppliger Leibundgut E; Gattiker HH; Manz MG; Müller AM; Goede JS
Oncologist; 2017 Apr; 22(4):480-483. PubMed ID: 28242791
[TBL] [Abstract][Full Text] [Related]
9. Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice.
Agerstam H; Järås M; Andersson A; Johnels P; Hansen N; Lassen C; Rissler M; Gisselsson D; Olofsson T; Richter J; Fan X; Ehinger M; Fioretos T
Blood; 2010 Sep; 116(12):2103-11. PubMed ID: 20554971
[TBL] [Abstract][Full Text] [Related]
10. Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome.
Chase A; Bryant C; Score J; Cross NC
Haematologica; 2013 Jan; 98(1):103-6. PubMed ID: 22875613
[TBL] [Abstract][Full Text] [Related]
11. 8p11 myeloproliferative syndrome preceded by t(8;9)(p11;q33), CEP110/FGFR1 fusion transcript: morphologic, molecular, and cytogenetic characterization of myeloid neoplasms associated with eosinophilia and FGFR1 abnormality.
Park TS; Song J; Kim JS; Yang WI; Song S; Kim SJ; Suh B; Choi JR
Cancer Genet Cytogenet; 2008 Mar; 181(2):93-9. PubMed ID: 18295660
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic application of next-generation sequencing in ZMYM2-FGFR1 8p11 myeloproliferative syndrome: A case report.
Wang Y; Wu X; Deng J; Yu H; Xu R; Zhu Z; Tu S; Hu Y
Cancer Biol Ther; 2016 Aug; 17(8):785-9. PubMed ID: 27415155
[TBL] [Abstract][Full Text] [Related]
13. [8p11 myeloproliferative syndrome].
Li F; Zhai YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):1073-7. PubMed ID: 23998615
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel partner gene, TPR, fused to FGFR1 in 8p11 myeloproliferative syndrome.
Li F; Zhai YP; Tang YM; Wang LP; Wan PJ
Genes Chromosomes Cancer; 2012 Sep; 51(9):890-7. PubMed ID: 22619110
[TBL] [Abstract][Full Text] [Related]
15. [The 8p11 myeloproliferative syndrome: a review of recent literature].
Kirito K
Rinsho Ketsueki; 2019; 60(9):1157-1165. PubMed ID: 31597839
[TBL] [Abstract][Full Text] [Related]
16. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1.
Macdonald D; Reiter A; Cross NC
Acta Haematol; 2002; 107(2):101-7. PubMed ID: 11919391
[TBL] [Abstract][Full Text] [Related]
17. Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders.
Ye Z; Zhan H; Mali P; Dowey S; Williams DM; Jang YY; Dang CV; Spivak JL; Moliterno AR; Cheng L
Blood; 2009 Dec; 114(27):5473-80. PubMed ID: 19797525
[TBL] [Abstract][Full Text] [Related]
18. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.
Chen J; Deangelo DJ; Kutok JL; Williams IR; Lee BH; Wadleigh M; Duclos N; Cohen S; Adelsperger J; Okabe R; Coburn A; Galinsky I; Huntly B; Cohen PS; Meyer T; Fabbro D; Roesel J; Banerji L; Griffin JD; Xiao S; Fletcher JA; Stone RM; Gilliland DG
Proc Natl Acad Sci U S A; 2004 Oct; 101(40):14479-84. PubMed ID: 15448205
[TBL] [Abstract][Full Text] [Related]
19. A case of 8p11 myeloproliferative syndrome with BCR-FGFR1 gene fusion presenting with trilineage acute leukemia/lymphoma, successfully treated by cord blood transplantation.
Morishige S; Oku E; Takata Y; Kimura Y; Arakawa F; Seki R; Imamura R; Osaki K; Hashiguchi M; Yakushiji K; Mizuno S; Yoshimoto K; Nagafuji K; Ohshima K; Okamura T
Acta Haematol; 2013; 129(2):83-9. PubMed ID: 23171834
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome.
Grand EK; Grand FH; Chase AJ; Ross FM; Corcoran MM; Oscier DG; Cross NC
Genes Chromosomes Cancer; 2004 May; 40(1):78-83. PubMed ID: 15034873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
